VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LABStandard BioTools Inc.
$0.54$223M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LAB logo

Standard BioTools Inc.

LAB
NASDAQ · Life Science Tools
$0.54
At close - Nov 17, 4:00 PM EST - USD
Market Cap$211M
P/E-5.4x
52W High$1.72
Volume4.36M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Stabilizing at Lower Base While Losses Persist

Standard BioTools' revenue has fallen from $46.7M in 2024Q4 to $19.4M in 2026Q3, but recent quarters near $19M to $21M suggest the base may be stabilizing at a much lower level.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

LAB price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-115% Peers

P/E is 115% below peer median

03

Market leadership

RS 21 · Lag

Laggard (Underperforming 79% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 3

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LAB-57.53%
S&P 500 (^GSPC)+7.21%
1-Year Return
LAB-55.42%
S&P 500 (^GSPC)+10.03%
3-Year Return
LAB-75.92%
S&P 500 (^GSPC)+48.85%
5-Year Return
LAB-88.62%
S&P 500 (^GSPC)+45.90%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$85M-51.1% YoY
Net income FY25
-$75M+46.1% YoY
Free cash flow FY25
-$83M+45.6% YoY
Operating margin FY25
-109.3%-8.9 pts YoY
ROIC (FY25)-20.7%
Avg ROIC 5Y-77.4%
ROE (TTM)-7.5%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 3, 2026
$0.03+250.0%
vs -$0.02
$19M+3.1%
vs $19M
Q3 2026
Aug 5, 2026
-$0.07-449.0%
vs -$0.01
$20M-3.4%
vs $21M
Q2 2026
May 5, 2026
-$0.02+0.0%
vs -$0.02
$21M+18.8%
vs $18M
Q1 2026
Feb 24, 2026
$0.06+300.0%
vs -$0.03
$24M+28.6%
vs $19M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

3 Stories
GlobeNewsWire·Oct 5, 2026
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries.

GlobeNewsWire·Sep 30, 2026
Standard BioTools Provides Update on Sale of Mass Cytometry Business

Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior

GuruFocus·Sep 11, 2026
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?

Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial bene

Filtered for Standard BioTools Inc.More Headlines
04

Compare before deciding

Benchmark LAB against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Standard BioTools Inc. (LAB)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LAB logoLABStandard BioTools Inc.Current
$0.54$211.16M-5.42-51.08%-46.44%-7.54%—
AZTA logoAZTAAzenta, Inc.
$45.81$2.11B-11.924.7%-26.86%-10.81%—
NTRA logoNTRANatera, Inc.
$287.47$41.17B-251.4435.9%-5.66%-9.18%—
PACB logoPACBPacific Biosciences of California, Inc.
$1.82$565.3M-4.323.89%-81.31%-2618.51%—
SEER logoSEERSeer, Inc.
$1.46$80.27M-1.2815.57%-457.86%-27.03%—
CDNA logoCDNACareDx, Inc
$74.56$3.85B31.8713.79%25.86%34.08%—

Compare LAB vs Peers

Standard BioTools Inc. (LAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AZTA

Most directly comparable listed peer for LAB.

Scale Benchmark

vs TMO

Larger-name benchmark to compare LAB against a more recognizable public peer.

Peer Set

Compare Top 5

vs AZTA, NTRA, PACB, SEER

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

LAB SEC Filings & Documents

Standard BioTools Inc. (LAB) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 3, 2026·SEC

Material company update

Aug 5, 2026·SEC

Material company update

Jul 28, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 16, 2026·SEC

FY 2025

Mar 11, 2025·SEC

FY 2024

Mar 1, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 3, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when LAB posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LAB Frequently Asked Questions

Standard BioTools Inc. (LAB) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Standard BioTools Inc.'s revenue?

Standard BioTools Inc. (LAB) reported $84.4M in revenue over the trailing twelve months. Revenue was $85.3M in fiscal year 2025. That is 1234% more than the $6.4M of fiscal year 2006.

How fast is Standard BioTools Inc. growing?

Standard BioTools Inc. (LAB) revenue fell by 22.0% over the trailing twelve months, compared with the twelve months before.

Is LAB profitable?

No. Standard BioTools Inc. (LAB) reported a net loss of $39.2M over the trailing twelve months.

Dividend & Returns
What is LAB's return on equity?

Standard BioTools Inc. (LAB) had a return on equity (ROE) of -7.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Standard BioTools Inc.'s free cash flow?

Standard BioTools Inc. (LAB) had negative free cash flow of $65.7M over the trailing twelve months.

What if you invested $1,000 in LAB back in 2006?

Total return calculator · dividends reinvested · 20+ years of data

See returns →